After receiving the ethical approval in Tanzania, NeuroSolve obtained the ethical clearance in Zambia too. The ethical clearance certificate will allow to conduct medical research on Neurocysticercosis also in Zambia.

NeuroSolve is a four-year project funded by the European Commission and EDCTP3, started on May 1, 2023. The African Institutions involved are: University of Dar es Salaam (Tanzania), Sokoine University of Agriculture (Tanzania), University of Zambia (Zambia); the European Institutions are: Universiteit Ghent (Belgium) and R-Evolution Worldwide Srl – Impresa Sociale (Italy), that is also the project Coordinator. NeuroSolve is committed to fight taeniasis/Neurocysticercosis (NCC) disease in Sub-Saharan Africa.

Potrebbe essere un'immagine raffigurante testo

Leave a Reply

Your email address will not be published. Required fields are marked *

Explore More

TB-SHIELD-WOMEN Proposal submitted to EDCTP3 call for innovative TB treatment research in sub-Saharan Africa

Our organization, together with an international consortium of partners, has submitted the project TB-SHIELD-WOMEN – Supportive nutritional Health Intervention for Enhanced recovery and Lowered Drug toxicity in vulnerable groups of

PRECISION-asympTB – Proposal submitted to EDCTP3 call for innovative TB treatment research in sub-Saharan Africa

PRECISION-asympTB was submitted under the EDCTP3 2026 Call on Tuberculosis.  Despite decades of global efforts, TB remains one of the leading infectious causes of death worldwide. One of the greatest challenges today

R-Evolution Worldwide visits accredited genomics and clinical trial facilities at Ifakara Health Institute

Tanzania, Morogoro Region – Ifakara On the occasion of the NeuroSolve 2026 Annual Meeting, we had the privilege of visiting the local facilities where critical research and diagnostic work are